Bavencio for metastatic Merkel Cell Carcinoma – Details


( Last Updated : April 6, 2018)
Generic Name:
Avelumab
Project Status:
Complete
Therapeutic Area:
metastatic Merkel Cell Carcinoma (mMCC)
Manufacturer:
EMD Serono - Pfizer Alliance
Brand Name:
Bavencio
Project Line:
Reimbursement Review
Project Number:
PC0124-000
NOC Status at Filing:
Pre NOC
NOC Date:

Details


Strength:
20 mg/mL
Tumour Type:
Skin & Melanoma
Indications:
metastatic Merkel Cell Carcinoma
Funding Request:
For the treatment of mMCC in previously treated adults
Pre Noc Submission:
Yes
Sponsor:
EMD Serono - Pfizer Alliance
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.